Novavax, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, specializing in the discovery, development, and commercialization of innovative vaccines to combat serious infectious diseases. With a robust pipeline, Novavax has made significant strides in vaccine technology, including its leading candidate for COVID-19, leveraging its proprietary protein-based nanoparticle platform. The company's commitment to addressing global health challenges positions it as a key player in the vaccine development landscape, attracting interest from institutional investors seeking exposure to cutting-edge public health solutions.